33 Results for "

CDC25A

" in MedChemExpress (MCE) Product Catalog:
Products (33)

33 Results for "CDC25A" in MCE Product Catalog:

37
37 Publications Verification
Cat. No.: HY-18174
CAS No.: 1234015-52-1
Synonyms: LY2606368
Research Areas:  

Cancer

Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity .
loading...
    loading...
37
37 Publications Verification
Cat. No.: HY-18174A
CAS No.: 1234015-54-3
Synonyms: LY2606368 dihydrochloride
Research Areas:  

Cancer

Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dihydrochloride inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dihydrochloride causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dihydrochloride shows potent anti-tumor activity .
loading...
    loading...
37
37 Publications Verification
Cat. No.: HY-18174E
CAS No.: 1234015-58-7
Synonyms: LY2606368 dimesylate
Research Areas:  

Cancer

Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dimesylate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dimesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dimesylate shows potent anti-tumor activity .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-108543
CAS No.: 93718-83-3
Purity:  ≥99.0%
Target:  

Phosphatase Apoptosis

Research Areas:  

Cancer

NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (Ki=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC50=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)) . NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-100034
CAS No.: 383907-43-5
Purity:  99.29%
Synonyms: DA-3003-1
Research Areas:  

Cancer

NSC 663284 (DA-3003-1) is a potent, cell-permeable, and irreversible Cdc25 dual specificity phosphatase inhibitor, has an IC50 for Cdc25B2 of 0.21 μM. NSC 663284 exhibits mixed competitive kinetics against Cdc25A, Cdc25B(2), and Cdc25C with Ki values of 29, 95, and 89 nM, respectively . NSC 663284 inhibits NSD2 (IC50 of 170 nM) through a direct interaction with the catalytic SET domain (Kd of 370 nM) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N7045
CAS No.: 142796-22-3
Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, Cdk2, Cdc25A), and activate Caspases (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-112776A
CAS No.: 1049740-43-3
Purity:  99.36%
Target:  

Phosphatase

Research Areas:  

Cancer

BN82002 hydrochloride is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 hydrochloride inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC50 values of 2.4, 3.9, 6.3, 5.4, and 4.6 µM, respectively. BN82002 hydrochloride displays ~20-fold greater selectivity over CD45 tyrosine phosphatase .
loading...
    loading...
Cat. No.: HY-112776
CAS No.: 396073-89-5
Target:  

Phosphatase

Research Areas:  

Cancer

BN82002 is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC50 values of 2.4, 3.9, 6.3, 5.4, and 4.6 µM, respectively. BN82002 displays ~20-fold greater selectivity over CD45 tyrosine phosphatase .
loading...
    loading...
Cat. No.: HY-132578
CAS No.: 2832887-40-6
Target:  

Phosphatase

Research Areas:  

Cancer

M5N36 is a potent and selective Cdc25C inhibitor with IC50 values of 0.15, 0.19, 0.06 µM for Cdc25A, Cdc25B, Cdc25C, respectively. M5N36 shows anti-proliferative activity and increases the expression of p-CDK1 and p-CDK2 .
loading...
    loading...
Cat. No.: HY-RS02291
Research Areas:  

Others

CDC25A Human Pre-designed siRNA Set A contains three designed siRNAs for CDC25A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-121065
CAS No.: 477603-18-2
Purity:  ≥95.0%
Synonyms: IRC-083065
Target:  

Phosphatase

Research Areas:  

Cancer

BN-82685 is a a quinone-based CDC25 inhibitor with IC50 of 201 nM, 117 nM, 109 nM, 160 nM, 249 nM, for CDC25C, CDC25C-cat, CDC25A, CDC25B2, CDC25B3, respectively. BN-82685 plays an important role in cancer research .
loading...
    loading...
Cat. No.: HY-W024644
CAS No.: 59147-84-1
Target:  

Phosphatase

Research Areas:  

Cancer

Hydroxyethylthio Vitamin K3 is a Cdc25 phosphatase inhibitor, with IC50 values of 4.56 μM and 23.63 μM for Cdc25A and Cdc25B, respectively. Hydroxyethylthio Vitamin K3 can be used in tumor research .
loading...
    loading...
Cat. No.: HY-128769
CAS No.: 2376577-06-7
Purity:  98.19%
Target:  

CDK

Research Areas:  

Cancer

M2N12 is a potent and highly selective cell division cycle 25C protein phosphatase (Cdc25C) inhibitor with an IC50 value of 0.09  μM. M2N12 also has promising activity against Cdc25A and Cdc25B with IC50 values of  0.53  μM and 1.39 μM, respectively. M2N12 has anti-tumor activity and can be used for cancer research .
loading...
    loading...
Cat. No.: HY-P4979
CAS No.: 851538-67-5
Research Areas:  

Cancer

Cdc25A (80-93) (human) is a polypeptide that controls the cell proliferation and tumorigenesis by a change in expression of proteins involved in cyclin D1 regulation and G1/S transition. Cdc25A (80-93) (human) can be used in cancer research .
loading...
    loading...
Cat. No.: HY-118529
CAS No.: 874351-38-9
Purity:  98.57%
Target:  

Phosphatase

Research Areas:  

Cancer

JUN-1111 is an irreversible and selective Cdc25 phosphatase inhibitor with IC50 values of 0.38, 1.8, 0.66, 28, 37 µM for Cdc25A, Cdc25B, Cdc25C, VHR, PTP1B, respectively. JUN-1111 induces cell cycle arrest at G1 and G2/M phases. JUN-1111 decreases the expression of phosphoCdk1 .
loading...
    loading...
Cat. No.: HY-RS17278
Research Areas:  

Others

Cdc25a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdc25a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS23732
Research Areas:  

Others

Cdc25a Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdc25a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-18174H
CAS No.: 2781996-46-9
Synonyms: LY2606368 lactate
Research Areas:  

Cancer

Prexasertib lactate (LY2606368 lactate) is the lactate form of Prexasertib (HY-18174). Prexasertib lactate is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib lactate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib lactate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib lactate shows potent anti-tumor activity .
loading...
    loading...
Cat. No.: HY-178296
CAS No.: 1146616-16-1
Target:  

Phosphatase

Research Areas:  

Cancer

VHR-IN-6 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 74 nM. VHR-IN-6 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.52 μM), CD45 (IC50 = 0.50 μM), Cdc25A (IC50 = 2.8 μM), PTP1B (IC50 = 0.42 μM), and HePTP (IC50 = 0.87 μM). VHR-IN-6 inhibits the proliferation of HeLa cells. VHR-IN-6 can be used for the research of cervical cancer .
loading...
    loading...
Cat. No.: HY-178297
CAS No.: 1146616-17-2
Target:  

Phosphatase

Research Areas:  

Cancer

VHR-IN-7 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 71 nM. VHR-IN-7 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.47 μM), CD45 (IC50 = 0.3 μM), Cdc25A (IC50 = 3.4 μM), PTP1B (IC50 = 0.59 μM), and HePTP (IC50 = 1.2 μM). VHR-IN-7 inhibits the proliferation of HeLa cells. VHR-IN-7 can be used for the research of cervical cancer .
loading...
    loading...